a public good project by the
Synthesis
Company
of California

© 2026

Ricardo E. Vilain | doi.page

0 works0 citations0 h-index

Ricardo E. Vilain

John Hunter Hospital(AU)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Cancer Genomics and Diagnostics, Immunotherapy and Immune Responses

Most-Cited Works

→ Whole-genome landscapes of major melanoma subtypes(2017)1,452 cited
→ PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials(2014)389 cited
→ PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma(2015)301 cited
→ Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma(2017)244 cited
→ Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome(2015)237 cited
→ Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types(2010)216 cited

→ PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients(2015)

141 cited

→ Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenase–deficient Gastrointestinal Stromal Tumors(2012)119 cited

→ PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma(2016)116 cited

→ Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases(2015)87 cited